Publikation

Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer.

Wissenschaftlicher Artikel/Review - 08.02.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Peres T, Aeppli S, Fischer S, Gysel K, Rothermundt C. Metronomic cyclophosphamide for bone marrow carcinomatosis in metastatic castration-resistant prostate cancer. J Cancer Res Clin Oncol 2024; 150:84.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
J Cancer Res Clin Oncol 2024; 150
Veröffentlichungsdatum
08.02.2024
eISSN (Online)
1432-1335
Seiten
84
Kurzbeschreibung/Zielsetzung

In some patients with prostate cancer, bone marrow carcinomatosis develops later in the course of the disease, which has a poor prognosis. These are often heavily pretreated patients in the castration-resistant situation for whom there are no other therapeutic options, because either all available systemic therapies have already been used or the use of one is not possible due to the cytopenias associated with bone marrow carcinomatosis. In our literature search, there are no data on this treatment in the setting available, especially no clinical trial or even randomized data. This case series is to determine the clinical efficacy of metronomic cyclophosphamide in patients with metastatic castration-resistant prostate cancer and bone marrow carcinomatosis, particularly with regard to stabilization of the blood count (thrombocytopenias) and thus the possibility of further (more toxic) lines of therapy.